Loading...

Innate Pharma

DB:IDD
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IDD
DB
€381M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Innate Pharma has significant price volatility in the past 3 months.
IDD Share Price and Events
7 Day Returns
0%
DB:IDD
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-12.6%
DB:IDD
-7.9%
DE Biotechs
-7.2%
DE Market
IDD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innate Pharma (IDD) 0% -8.9% -16.8% -12.6% -54.1% -19.2%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • IDD underperformed the Biotechs industry which returned -7.9% over the past year.
  • IDD underperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
IDD
Industry
5yr Volatility vs Market
Related Companies

IDD Value

 Is Innate Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Innate Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Innate Pharma.

DB:IDD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IDD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 33%) (1.19%))
1.313
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.313 * 6.65%)
8.96%

Discounted Cash Flow Calculation for DB:IDD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Innate Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:IDD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.96%)
2019 -21.80 Analyst x1 -20.01
2020 -60.70 Analyst x2 -51.13
2021 -57.00 Analyst x1 -44.06
2022 -9.00 Analyst x1 -6.38
2023 7.00 Analyst x1 4.56
2024 10.69 Est @ 52.69% 6.39
2025 14.64 Est @ 36.95% 8.03
2026 18.43 Est @ 25.93% 9.28
2027 21.79 Est @ 18.22% 10.07
2028 24.59 Est @ 12.82% 10.42
Present value of next 10 years cash flows €-72.84
DB:IDD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €24.59 × (1 + 0.23%) ÷ (8.96% – 0.23%)
€282.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €282.18 ÷ (1 + 8.96%)10
€119.62
DB:IDD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €-72.84 + €119.62
€46.78
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €46.78 / 63.91
€0.73
DB:IDD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:IDD represents 0.99664x of ENXTPA:IPH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99664x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 0.73 x 0.99664
€0.73
Value per share (EUR) From above. €0.73
Current discount Discount to share price of €5.94
= -1 x (€5.94 - €0.73) / €0.73
-714.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Innate Pharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innate Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innate Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IDD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.05
ENXTPA:IPH Share Price ** ENXTPA (2019-04-17) in EUR €5.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innate Pharma.

DB:IDD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:IPH Share Price ÷ EPS (both in EUR)

= 5.96 ÷ 0.05

114.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innate Pharma is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Innate Pharma is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Innate Pharma's expected growth come at a high price?
Raw Data
DB:IDD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 114.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-32.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:IDD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 114.89x ÷ -32.4%

-3.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innate Pharma earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Innate Pharma's assets?
Raw Data
DB:IDD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €2.83
ENXTPA:IPH Share Price * ENXTPA (2019-04-17) in EUR €5.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:IDD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:IPH Share Price ÷ Book Value per Share (both in EUR)

= 5.96 ÷ 2.83

2.11x

* Primary Listing of Innate Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innate Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Innate Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Innate Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IDD Future Performance

 How is Innate Pharma expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-32.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innate Pharma expected to grow at an attractive rate?
  • Innate Pharma's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Innate Pharma's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Innate Pharma's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IDD Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IDD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -32.4%
DB:IDD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 0.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IDD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IDD Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 72 7 -71 1
2022-12-31 99 -9 -28 1
2021-12-31 106 -57 -47 1
2020-12-31 92 -21 -45 4
2019-12-31 72 2 -28 3
DB:IDD Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 94 -33 3
2018-09-30 70 -46 -19
2018-06-30 46 -59 -41
2018-03-31 45 -53 -45
2017-12-31 44 -48 -48
2017-09-30 55 -43 -28
2017-06-30 66 -38 -8
2017-03-31 66 -37 3
2016-12-31 66 -37 13
2016-09-30 53 -33 5
2016-06-30 41 -29 -2
2016-03-31 33 86 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Innate Pharma's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Innate Pharma's revenue is expected to grow by 0.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IDD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Innate Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IDD Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.94 -0.94 -0.94 1.00
2022-12-31 -0.40 -0.40 -0.40 1.00
2021-12-31 -0.68 -0.68 -0.68 1.00
2020-12-31 -0.70 -0.42 -0.96 3.00
2019-12-31 -0.17 -0.17 -0.17 1.00
DB:IDD Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.05
2018-09-30 -0.33
2018-06-30 -0.73
2018-03-31 -0.81
2017-12-31 -0.89
2017-09-30 -0.52
2017-06-30 -0.14
2017-03-31 0.05
2016-12-31 0.23
2016-09-30 0.10
2016-06-30 -0.03
2016-03-31 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innate Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Innate Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innate Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IDD Past Performance

  How has Innate Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innate Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innate Pharma's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Innate Pharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Innate Pharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Innate Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innate Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IDD Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 93.95 3.05 18.14
2018-09-30 70.19 -19.08 16.41
2018-06-30 46.43 -41.22 14.67
2018-03-31 45.23 -44.80 15.84
2017-12-31 44.03 -48.39 17.02
2017-09-30 55.17 -27.97 15.56
2017-06-30 66.31 -7.55 14.11
2017-03-31 66.02 2.55 11.81
2016-12-31 65.72 12.64 9.52
2016-09-30 53.45 5.39 8.07
2016-06-30 41.19 -1.85 6.62
2016-03-31 33.16 -4.28 6.31
2015-12-31 25.14 -6.71 6.01
2015-09-30 16.63 -12.67 4.96
2015-06-30 8.13 -18.63 3.90
2015-03-31 7.87 -19.14 4.41
2014-12-31 7.62 -19.65 4.92
2014-09-30 10.72 -14.63 6.41
2014-06-30 13.81 -9.61 7.91
2014-03-31 15.23 -6.25 7.73
2013-12-31 16.65 -2.89 7.55
2013-09-30 15.10 -3.20 7.13
2013-06-30 13.54 -3.50 6.71
2013-03-31 13.91 -3.35 6.75
2012-12-31 14.28 -3.20 6.79
2012-09-30 15.35 -3.49 6.96
2012-06-30 16.42 -3.78 7.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Innate Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Innate Pharma used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Innate Pharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Innate Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innate Pharma has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IDD Health

 How is Innate Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innate Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innate Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innate Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Innate Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 70.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innate Pharma Company Filings, last reported 3 months ago.

DB:IDD Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 169.44 4.52 167.53
2018-09-30 169.44 4.52 167.53
2018-06-30 87.17 5.23 96.88
2018-03-31 87.17 5.23 96.88
2017-12-31 85.96 5.86 116.11
2017-09-30 85.96 5.86 116.11
2017-06-30 68.91 4.66 171.48
2017-03-31 68.91 4.66 171.48
2016-12-31 86.17 5.33 197.69
2016-09-30 86.17 5.33 197.69
2016-06-30 69.20 4.08 203.93
2016-03-31 69.20 4.08 203.93
2015-12-31 72.07 3.75 235.91
2015-09-30 72.07 3.75 235.91
2015-06-30 69.18 3.98 278.93
2015-03-31 69.18 3.98 278.93
2014-12-31 74.63 4.21 69.24
2014-09-30 74.63 4.21 69.24
2014-06-30 85.02 4.43 78.91
2014-03-31 85.02 4.43 78.91
2013-12-31 40.29 4.82 41.35
2013-09-30 40.29 4.82 41.35
2013-06-30 21.48 4.08 24.74
2013-03-31 21.48 4.08 24.74
2012-12-31 23.36 4.51 32.62
2012-09-30 23.36 4.51 32.62
2012-06-30 24.65 5.20 37.74
  • Innate Pharma's level of debt (2.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (11.8% vs 2.7% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are not well covered by earnings (EBIT is 2.1x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Innate Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innate Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IDD Dividends

 What is Innate Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Innate Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Innate Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Innate Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Innate Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IDD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IDD Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Innate Pharma has not reported any payouts.
  • Unable to verify if Innate Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Innate Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Innate Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Innate Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Innate Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innate Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innate Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IDD Management

 What is the CEO of Innate Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mondher Mahjoubi
COMPENSATION €749,503
AGE 60
TENURE AS CEO 2.3 years
CEO Bio

Dr. Mondher Mahjoubi, M.D., has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016. Dr. Mahjoubi has more than 20 years of experience working in clinical development, marketing and strategy in Europe and the USA for leading pharmaceutical companies in the field of oncology such as Aventis, Sanofi, Roche-Genentech and AstraZeneca. Dr. Mahjoubi served as Senior Vice President, Therapeutic Area Head of Oncology, Global Product and Portfolio Strategy at AstraZeneca PLC until January 2017. He is instrumental in driving the oncology strategy at AstraZeneca and beforehand at Genentech. Dr. Mahjoubi is a medical oncologist trained at Institut Gustave Roussy (Paris-Villejuif). Dr. Mahjoubi holds a MD from the University of Tunis and certifications in Medical Oncology from the University of Tunis and University of Paris Sud and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis. He is trained as a medical oncologist and is a member of the American Society of Clinical Oncology and European Society of Medical Oncology.

CEO Compensation
  • Mondher's compensation has increased in line with Innate Pharma recently becoming profitable.
  • Mondher's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Innate Pharma management team in years:

2.3
Average Tenure
57
Average Age
  • The tenure for the Innate Pharma management team is about average.
Management Team

Hervé Brailly

TITLE
Co-Founder & Chairman of Supervisory Board
COMPENSATION
€150K
AGE
57
TENURE
20.3 yrs

Mondher Mahjoubi

TITLE
Chairman of Executive Board & CEO
COMPENSATION
€750K
AGE
60
TENURE
2.3 yrs

Yannis Morel

TITLE
Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board
COMPENSATION
€269K
AGE
45
TENURE
3.8 yrs

Laure-Hélène Mercier

TITLE
Executive VP
AGE
40
TENURE
2.3 yrs

Eric Vivier

TITLE
Senior VP & Chief Scientific Officer
AGE
54
TENURE
1.3 yrs

Odile Belzunce

TITLE
Senior Vice President of Compliance & Portfolio Management
TENURE
0.3 yrs

Pierre Dodion

TITLE
Executive VP & Chief Medical Officer
AGE
64
TENURE
4.6 yrs

Jennifer Butler

TITLE
Executive VP & General Manager of US
TENURE
0.1 yrs

Catherine Moukheibir

TITLE
COMPENSATION
€280K
AGE
59
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Innate Pharma board of directors in years:

1.8
Average Tenure
57
Average Age
  • The average tenure for the Innate Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Hervé Brailly

TITLE
Co-Founder & Chairman of Supervisory Board
COMPENSATION
€150K
AGE
57
TENURE
2.3 yrs

Irina Staatz-Granzer

TITLE
Vice Chairman of Supervisory Board
COMPENSATION
€28K
AGE
58

Gilles Brisson

TITLE
Member of Supervisory Board
COMPENSATION
€48K
AGE
66
TENURE
11.8 yrs

Patrick Langlois

TITLE
Member of Supervisory Board
COMPENSATION
€40K
AGE
73
TENURE
8.9 yrs

Marcus Schindler

TITLE
Member of Supervisory Board
AGE
52
TENURE
1.1 yrs

Olivier Martinez

TITLE
Observer to Supervisory Board
AGE
48
TENURE
1.8 yrs

Véronique Chabernaud

TITLE
Member of Supervisory Board
COMPENSATION
€30K
AGE
57
TENURE
4 yrs

Maïlys Ferrere

TITLE
Member of Supervisory Board
AGE
56
TENURE
1.8 yrs

Jean-Yves Blay

TITLE
Member of Supervisory Board
AGE
56
TENURE
1.3 yrs

Sebastian Amigorena

TITLE
Scientific & Medical Advisory Board Member
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Innate Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innate Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IDD News

Simply Wall St News

IDD Company Info

Description

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.

Details
Name: Innate Pharma S.A.
IDD
Exchange: DB
Founded: 1999
€380,927,916
63,914,080
Website: http://www.innate-pharma.com
Address: Innate Pharma S.A.
117 Avenue de Luminy,
BP 30191,
Marseille,
Provence-Alpes-Côte d'Azur, 13009,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA IPH Category O Ordinary Shares Euronext Paris FR EUR 01. Nov 2006
OTCPK IPHY.F Category O Ordinary Shares Pink Sheets LLC US USD 01. Nov 2006
DB IDD Category O Ordinary Shares Deutsche Boerse AG DE EUR 01. Nov 2006
LSE 0EVI Category O Ordinary Shares London Stock Exchange GB EUR 01. Nov 2006
SWX IPH Category O Ordinary Shares SIX Swiss Exchange CH CHF 01. Nov 2006
BATS-CHIXE IPHP Category O Ordinary Shares BATS 'Chi-X Europe' GB EUR 01. Nov 2006
Number of employees
Current staff
Staff numbers
195
Innate Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 21:30
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.